Consistent with its lipid-regulatory effects, our findings clearly suggest that RRBE could exert anti-inflammatory, antioxidant, and anti-apoptotic effects against HFD-induced hepatic injury by modulating the transcriptional expression of specific genes in the liver responsible for these effects, including the NF-κB target genes-iNOS, p47phox NOX subunit, pro-apoptotic Bax, and anti-apoptotic Bcl-2, implying that RRBE may mitigate the transition to more severe stages of NAFLD. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatotic liver disease.